About Aldeyra
Aldeyra is a publicly listed company based in Lexington (United States) founded in 2004. Drug candidates for immune-mediated diseases are developed by Aldeyra. Aldeyra has raised $4.79 million across 6 funding rounds from investors including Hercules Capital, Perceptive Advisors and Sphera Fund. The company has 9 employees. Aldeyra has completed 1 acquisition, including Helio Vision. Aldeyra offers products and services including RASP Modulator Platform and ADX-2191. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its legal entity is Aldeyra Therapeutics, Inc. Its competitors include Annexon, Gyroscope and MeiraGTx; 1 of its 3 listed competitors has raised funding.
Company details
Aldeyra was founded in 2004 and is based in Lexington, United States. Operations are conducted in the biotechnology sector, where drug candidates are developed to address immune-mediated diseases. The pipeline targets inflammatory cells associated with ocular and systemic conditions, including Reproxalap for dry eye disease and allergic conjunctivitis, as well as ADX-2191 for proliferative vitreoretinopathy and other programs.
- Headquarters Lexington, United States
- Employees 9
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website aldeyra.com
- Social LinkedIn Facebook
- Legal Name Aldeyra Therapeutics, Inc.
- Net Profit-$33.85 M (USD)39.4as on Dec 31, 2025
- EBITDA-$35.01 M (USD)41.52as on Dec 31, 2025
- Total Equity Funding$4.79M (USD)
in 6 rounds
- InvestorsHercules Capital
& 3 more
- Employee Count9
- Investments & Acquisitions
Products & Services of Aldeyra
Aldeyra offers a comprehensive portfolio of products and services, including RASP Modulator Platform and ADX-2191.
Modulates immunological systems to inhibit inflammatory cells in diseases.
Treats signs and symptoms of dry eye disease through targeted mechanisms.
Funding Insights of Aldeyra
Aldeyra has successfully raised a total of $4.79M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.79M
- Total Rounds 6
- First Round $4.79M
(Jan 2013)
- Investors Count 4
All 6 funding rounds of Aldeyra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | Post-IPO | – | – | ||
| Mar 2019 | $60M | Debt – Conventional | – | – | |
| Feb 2019 | $10M | Post-IPO | – | – | – |
| Feb 2015 | $2M | Post-IPO | – | – | – |
| Jan 2015 | $7.79M | Post-IPO | – | – | |
| Jan 2013 | $4.79M | Series A | – | – | – |
4 investors in total: 4 institutional.
Investors in Aldeyra
Aldeyra has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Perceptive Advisors and Sphera Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Manages hedge funds with long/short equity and real estate strategies for investors. | 2004 | spherafund.com | Tel Aviv, Israel | |
Manages long/short portfolios in publicly traded biotech and medical device firms. | 1999 | dafnacapital.com | Los Angeles, United States |
Investor details for Aldeyra
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aldeyra
15 people are tracked at Aldeyra (8 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
David J. Clark | Chief Medical Officer | Leadership |
Stephen G. Machatha | Senior Vice President, Technical Operations | Leadership |
David Noskowitz | Vice President, Regulatory Affairs | Leadership |
Christopher Pearson | Vice President, Commercial Development and Strategy | Leadership |
Todd C. Brady | CEO & President | Leadership |
Lise L. Kjems | Vice President, Clinical Development | Leadership |
Laura Nichols | Associate Director Of Investor Relations & Business Operations | Leadership |
Charles Montgomery | Senior Director, CMC | Leadership |
Richard H. Douglas | Chairman of the Board | Board & advisors |
Martin J. Joyce | Director | Board & advisors |
Neal Walker | Director | Board & advisors |
Gary Phillips | Director | Board & advisors |
Jesse I. Treu | Director | Board & advisors |
Ben Bronstein | Director | Board & advisors |
Ginny Kaligian | Senior Clinical Trial Associate | Team |
Complete people profiles for Aldeyra
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aldeyra
Aldeyra is a publicly listed company on the NASDAQ with ticker symbol ALDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 May 2014
- Listed onNASDAQ: ALDX
- Listed entityAldeyra Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS01438T1060
- Share price$0.90 (-0.66% on the day) · 2026-10-13
- Market capitalisation$54.3M
- EPS (diluted, trailing year)$-0.38
- Volume (last session)1,457,617
Financials of Aldeyra
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$33.9M | -$35.0M | |
| 2024 | -$55.9M | -$59.9M | |
| 2023 | -$37.5M | -$42.5M | |
| 2022 | -$62.0M | -$62.4M | |
| 2021 | -$57.8M | -$56.0M |
Detailed financial statements for Aldeyra
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aldeyra
Aldeyra has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Helio Vision.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of small molecule based therapeutics for the treatment of eye diseases | heliovisioninc.com | Waltham, United States | 2016 | Jan 2019 | $12.5M |
Complete acquisition details for Aldeyra
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Aldeyra
5 dated milestones of Aldeyra across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Aldeyra is founded.
- Funding First funding round of $4.8M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Helio Vision.
- Funding Latest funding round, Post-IPO,.
Competitors of Aldeyra
Aldeyra has 3 listed competitors in our database, 1 of them funded. They include Annexon, Gyroscope and MeiraGTx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| gyroscope.cc | 2016 | San Francisco, United States | Mobile SDK developed for app engagement and monetization strategies. | |||
| meiragtx.com | 2015 | New York, United States | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. |
Detailed competitors of Aldeyra
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aldeyra
The website of Aldeyra (aldeyra.com) receives about 5.3K visits a month and ranks #3,362,746 among all websites worldwide, #4,404 in Biotechnology and Pharmaceuticals.
- Monthly visits5.3K
▼ 2.2% vs previous month
- Unique visitors2.3K
per month
- Global rank#3,362,746
among all websites
- Category rank#4,404
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit2.0
- Average visit40 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Aldeyra. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| endpts.com | 100% | 8.4K | #3,077,209 | View details | |
| managedhealthcareexecutive.com | 60% | #629,898 | View details | ||
healio.com | healio.com | 40% | #72,463 | – |
Top companies in Ophthalmology
3 companies that operate in the same segment as Aldeyra (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 24.69 B | 25,941 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aldeyra
Complete news archive for Aldeyra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aldeyra
Aldeyra was founded in 2004 and raised its 1st funding round 9 years after it was founded.
Aldeyra is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Aldeyra is a funded company, having raised a total of $4.79M across 6 funding rounds to date. The company's 1st funding round was a Series A of $4.79M, raised on Jan 2013.
Aldeyra has 9 employees.
Aldeyra was founded in 2004 and is based in Lexington, United States. Operations are conducted in the biotechnology sector, where drug candidates are developed to address immune-mediated diseases. The pipeline targets inflammatory cells associated with ocular and systemic conditions, including Reproxalap for dry eye disease and allergic conjunctivitis, as well as ADX-2191 for proliferative vitreoretinopathy and other programs.
Aldeyra offers RASP Modulator Platform and ADX-2191.
Yes, Aldeyra is publicly traded on NASDAQ under the ticker symbol ALDX.
Aldeyra has made 1 acquisition, including Helio Vision.
Aldeyra has 4 investors. Key investors include Hercules Capital, Perceptive Advisors, Sphera Fund, and DAFNA Capital Management.
Aldeyra operates through Aldeyra Therapeutics, Inc..